Beacon is working with our client partner to build awareness and prescriptions for a different treatment that can help people with hemophilia A or B with inhibitors move on from bleeds. This campaign targets HCPs, patients, and caregivers to:

  • Reinforce that living with an inhibitor can be unpredictable and that more bypassing treatment options are needed
  • Introduce the first FDA-approved bypassing treatment in over 20 years—an agent that is molecularly different from other bypassing agents
  • Position SEVENFACT as the bypassing agent that delivers rapid, predictable, and reliable control of mild/moderate bleeds to help people with hemophilia A or B with inhibitors move on with more predictability in their lives

A different way to help people with hemophilia A or B with inhibitors move on

See how our launch of the first inhibitor bypassing agent approved in the US in over 20 years met the need of HCPs, patients, and caregivers for rapid, predictable, reliable control of bleeds.

Share

©2021 Beacon Healthcare Communications, Inc. All Rights Reserved.